Mazor Robotics Announces World’s First Renaissance Asleep Deep Brain Stimulation Procedure
ORLANDO, Fla., March 25, 2014 – Mazor Robotics, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced that for the first time ever, a surgeon utilized Mazor Robotics Renaissance® Guidance System to perform an Asleep Deep Brain Stimulation (DBS) procedure earlier this month at Littleton Adventist Hospital in Littleton, CO.
The team was led by neurosurgeon Dr. David VanSickle of the Denver DBS Center. The patient, a 65-year-old male recently diagnosed with Parkinson’s, was treated for tremors and is responding well, according to Dr. VanSickle.
“Using the Renaissance system provides much more accuracy and holds the trajectory,” said Dr. VanSickle. “Because of this, more patients have the option of being asleep during the procedure than before. This is not only helpful for the patient and relieves a great deal of anxiety, but it enables the doctor to perform the procedure quicker, with less complication and fewer probes into the brain.”
“New research recently published in the New England Journal of Medicine, shows that undergoing DBS in the earlier stages of Parkinson’s disease is extremely effective, contrary to earlier recommendations that patients must have the disease for at least seven years to see the benefits of DBS,” said Dr. VanSickle. “The research also found DBS to be more effective than medications in controlling tremors in patients with Parkinson’s disease.”
Mazor Robotics Renaissance system is the first and only of its kind cleared by the US Food and Drug Administration for spine and brain surgery.
To date, thousands of spine procedures have been performed with the Renaissance system, ranging from minimally-invasive one-level fusions to complex deformity reconstructions. Dr. VanSickle is among the first to use the system for DBS.
Mazor Robotics is dedicated to the development and marketing of innovative surgical guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance, is a state-of-the-art surgical guidance system that enables surgeons to conduct spine and brain procedures in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding increased interest from surgeons and hospital administrators, the benefits and future value of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.